Nuvectis Pharma, Inc. (NVCT)
After hours:
| Previous close | 6.70 |
| Open | 6.80 |
| Bid | 6.66 x 100 |
| Ask | 6.85 x 100 |
| Day's range | 6.61 - 6.98 |
| 52-week range | 5.85 - 14.96 |
| Volume | |
| Avg. volume | 100,406 |
| Market cap | 125.906M |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
Business WirePESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
LONDON, September 16, 2024--Summit Therapeutics’ Breakthrough with Ivonescimab
GlobeNewswireNuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. EventH.C. Wainwright Global Investment ConferenceDateSeptember 9,
- GlobeNewswire
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration (“FDA”) for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) AR
